NanoMedicine Centre (NMC) offers expertise and infrastructure for the formulation and comprehensive characterization of biotherapeutics in nanoparticle-based systems ‘nanomedicines’

NanoMedicine Centre

NMC is part of the Ghent Research Group on Nanomedicines at Ghent University, which has over 20 years of expertise in nanomedicine and nucleic acid delivery.

NMC specializes in formulating nucleic acids, including mRNA vaccines, utilizing state-of-the-art lipid nanoparticle (LNP) technology.

It is our ambition to work at the forefront of nanomedicine research and to facilitate the transition of novel concepts from lab bench to first clinical testing.

Services

Characterization of Nanomedicines

NMC is establishing a validated toolbox that integrates cutting-edge assays for a comprehensive characterization of critical parameters to the development, production and quality control of nanomedicines.

Advanced analytical techniques for understanding the stability and heterogeneity of nanomedicines; e.g. AF4, Cryo-EM.

GMP compliant methods for measuring particle size-, zeta potential, lipid identity and mRNA integrity.

Biological evaluation of nanomedicines

Learn more

VaxAdvance

VaxAdvance unites four leading entities:

NMC: Formulation, preclinical development, QC testing

CellGENTherapies: GMP production, QC testing, IMPD writing

Core ARTH Animal Facilities: Advanced infrastructure, services and expertise for conducting preclinical (bio)medical (laboratory animal) research

Center for Vaccinology (CEVAC): Clinical trail unit, Immuno-monitoring

Together providing comprehensive services for developing and producing clinical batches of next-generation vaccines, including mRNA and saRNA platforms.

Our goal is to accelerate breakthroughs in vaccine and therapeutic development from the lab bench to real-world clinical applications.

Vaxadvance

Services

NMC is open for collaboration with academic research groups and companies on a fee-for-service basis or as partner in R&D co-development projects. A dedicated team is on-hand to develop, test and optimize nanomedicine products and support with technical problem-solving, assay development and knowledge on GMP and regulatory processes.

Formulation

Encapsulation of
nucleic acids and other
biotherapeutics in state-of-
the-art liposomes or
lipid nanoparticles (LNPs).

Characterization

Analytical- and biological
characterization of
nanomedicines,
including QC in GMP.

Translation

Supporting the transition of
nanomedicines
from early concept to
first clinical testing